xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05997433</url>
    </required_header>
    <id_info>
      <org_study_id>SHARE2302</org_study_id>
      <nct_id>NCT05997433</nct_id>
    </id_info>
    <brief_title>Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori（SHARE2302)</brief_title>
    <official_title>Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori : A Multicenter Randomized Non-Inferiority Trial</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Shandong University</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>Zibo Maternal and Child Health Hospital</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>Zaozhuang Municipal Hospital</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>Binzhou Maternal and Child Health Hospital</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>Jinxiang County People's Hospital</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>Linyi Yizhou Hospital</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>Yantai Penglai Traditional Chinese Medicine Hospital</agency>
        <agency_class>Other</agency_class>
      </collaborator>
    </sponsors>
    <source>Shandong University</source>
    <oversight_info>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        Helicobacter pylori (H. pylori) infection is a common global infectious disease of the&#xD;
        gastrointestinal tract. Helicobacter pylori eradication can effectively prevent the&#xD;
        development of stomach cancer.The researchers collect H.pylori-positive patients who need&#xD;
        native therapy. The subjects were randomized to receive7 days and 14 days of bismuth&#xD;
        quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the&#xD;
        13C-urea breath test. Calculate the eradication rates, adverse reaction rates and patient&#xD;
        compliance of each group.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Related studies have shown that 7-day bismuth quadruple therapy is not inferior to 14-day&#xD;
        bismuth quadruple therapy in the eradication of clarithromycin-resistant H. pylori.The&#xD;
        results of the current study conducted by our team on the eradication of H. pylori in 10-day&#xD;
        versus 14-day courses of bismuth quadruple therapy showed that the 10-days (92.09%) was not&#xD;
        inferior to the 14-days(92.38%), but the incidence of adverse effects was significantly lower&#xD;
        in the 10-day courses than in the 14-days(30.62%). If it can be demonstrated that the&#xD;
        eradication rate of the 7-day course of bismuth quadruplex is close to that of the 14-days,&#xD;
        then the 7-day course may be chosen.&#xD;
  &#xD;
        The researchers collect H.pylori-positive patients who need native therapy. If the subject&#xD;
        meets the selection criteria but not the exclusion criteria, and signs an informed consent&#xD;
        form, the researchers randomized the subjects in groups: subjects received 7days or 14days&#xD;
        bismuth quadruple eradication therapy. The medication of groups are as follows. 6-8 weeks&#xD;
        after the eradication treatment, the subjects will review the 13C-urea breath test, and the&#xD;
        researcher records the results.&#xD;
  &#xD;
        After all subjects were tested, the eradication rates, adverse reaction rates and patient&#xD;
        compliance of each group were calculated.&#xD;
  &#xD;
        According to therapy, it is randomized into a 7days treatment group and a 14 days treatment&#xD;
        group. The two groups of bismuth quadruple regimens are the same, as follows:&#xD;
  &#xD;
        7days group: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid&#xD;
        14days group: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">September 2, 2023</start_date>
    <completion_date type="Anticipated">August 30, 2024</completion_date>
    <primary_completion_date type="Anticipated">August 30, 2024</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <intervention_model_description>Parallel Assignment</intervention_model_description>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Eradication rate</measure>
      <time_frame>Immediately after follow-up check</time_frame>
      <description>Both intention to treat (ITT) and per-protocol (PP) analyses will be used for the assessment of the eradication rates of Helicobacter pylori infections in two groups. The ITT analysis includes all randomly assigned patients who take at least one dose of the study medications. The PP analysis is limited to patients who take over 90% of the study medications and complete follow-up.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Rate of adverse reactions</measure>
      <time_frame>Immediately after follow-up check</time_frame>
      <description>Rate of adverse reactions</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Patient compliance</measure>
      <time_frame>Immediately after follow-up check</time_frame>
      <description>Good compliance is defined as the actual dosage is within the range of 80%-100% of the dosage that should be taken.</description>
    </secondary_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">254</enrollment>
    <condition>Helicobacter Pylori Infection</condition>
    <arm_group>
      <arm_group_label>7 days</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid</description>
    </arm_group>
    <arm_group>
      <arm_group_label>14 days</arm_group_label>
      <arm_group_type>Active Comparator</arm_group_type>
      <description>Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid</description>
    </arm_group>
    <intervention>
      <intervention_type>Procedure</intervention_type>
      <intervention_name>7days bismuth quadruple</intervention_name>
      <description>Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid*7days</description>
      <arm_group_label>7 days</arm_group_label>
      <other_name>Amoxicillin</other_name>
      <other_name>Tetracycline</other_name>
      <other_name>Bismuth</other_name>
      <other_name>Tegoprazan</other_name>
    </intervention>
    <intervention>
      <intervention_type>Procedure</intervention_type>
      <intervention_name>14 days bismuth quadruple</intervention_name>
      <description>Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid*14days</description>
      <arm_group_label>14 days</arm_group_label>
      <other_name>Amoxicillin</other_name>
      <other_name>Tetracycline</other_name>
      <other_name>Bismuth</other_name>
      <other_name>Tegoprazan</other_name>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            1. Patients aged 18-70.&#xD;
  &#xD;
            2. Without active hepatitis.&#xD;
  &#xD;
            3. Helicobacter pylori infection (either positive for rapid urease test, C13/C14 urea&#xD;
               breath test).&#xD;
  &#xD;
            4. Patients who have not previously received helicobacter pylori eradication therapy.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            1. Patients with serious underlying diseases, such as liver insufficiency (Aspartate&#xD;
               aminotransferase or alanine aminotransferase greater than the normal value), renal&#xD;
               insufficiency (Cr≥2.0mg/dL or glomerular filtration rate &lt;50 ml/min),&#xD;
               immunosuppression, malignant tumors, Coronary heart disease or coronary artery&#xD;
               stenosis ≥75%.&#xD;
  &#xD;
            2. Patients who are pregnant or lactating or unwilling to take contraceptive measures&#xD;
               during the trial.&#xD;
  &#xD;
            3. Patients with active gastrointestinal bleeding.&#xD;
  &#xD;
            4. Patients with a history of upper gastrointestinal surgery.&#xD;
  &#xD;
            5. Patients allergic to treatment drugs.&#xD;
  &#xD;
            6. Patients with medication history of bismuth agents, antibiotics, proton pump inhibitor&#xD;
               and other drugs within 4 weeks.&#xD;
  &#xD;
            7. Patients with other behaviors that may increase the risk of illness, such as alcohol&#xD;
               and drug abuse.&#xD;
  &#xD;
            8. Patients who are unwilling or incapable to provide informed consents.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>70 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Yanqing Li, Ph.D</last_name>
      <role>Principal Investigator</role>
      <affiliation>Qilu Hospital of Shandong University</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Yanqing Li, Ph.D</last_name>
      <phone>+8653188369277</phone>
      <email>liyanqing@sdu.edu.cn</email>
    </overall_contact>
    <results_reference>
      <citation>Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong VWS, Wu JCY, Chan FKL, Sung JJY, Kaplan GG, Ng SC. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017 Aug;153(2):420-429. doi: 10.1053/j.gastro.2017.04.022. Epub 2017 Apr 27.</citation>
      <PMID>28456631</PMID>
    </results_reference>
    <results_reference>
      <citation>Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007 Jun;56(6):772-81. doi: 10.1136/gut.2006.101634. Epub 2006 Dec 14.</citation>
      <PMID>17170018</PMID>
    </results_reference>
    <results_reference>
      <citation>Cho JH, Jin SY. Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea. World J Clin Cases. 2022 Jul 6;10(19):6349-6359. doi: 10.12998/wjcc.v10.i19.6349.</citation>
      <PMID>35979311</PMID>
    </results_reference>
    <results_reference>
      <citation>Zhou XZ, Lyu NH, Zhu HY, Cai QC, Kong XY, Xie P, Zhou LY, Ding SZ, Li ZS, Du YQ; National Clinical Research Center for Digestive Diseases (Shanghai), Gastrointestinal Early Cancer Prevention &amp; Treatment Alliance of China (GECA), Helicobacter pylori Study Group of Chinese Society of Gastroenterology and Chinese Alliance for Helicobacter pylori Study.. Large-scale, national, family-based epidemiological study on Helicobacter pylori infection in China: the time to change practice for related disease prevention. Gut. 2023 May;72(5):855-869. doi: 10.1136/gutjnl-2022-328965. Epub 2023 Jan 23.</citation>
      <PMID>36690433</PMID>
    </results_reference>
    <results_reference>
      <citation>Ding SZ, Du YQ, Lu H, Wang WH, Cheng H, Chen SY, Chen MH, Chen WC, Chen Y, Fang JY, Gao HJ, Guo MZ, Han Y, Hou XH, Hu FL, Jiang B, Jiang HX, Lan CH, Li JN, Li Y, Li YQ, Liu J, Li YM, Lyu B, Lu YY, Miao YL, Nie YZ, Qian JM, Sheng JQ, Tang CW, Wang F, Wang HH, Wang JB, Wang JT, Wang JP, Wang XH, Wu KC, Xia XZ, Xie WF, Xie Y, Xu JM, Yang CQ, Yang GB, Yuan Y, Zeng ZR, Zhang BY, Zhang GY, Zhang GX, Zhang JZ, Zhang ZY, Zheng PY, Zhu Y, Zuo XL, Zhou LY, Lyu NH, Yang YS, Li ZS; National Clinical Research Center for Digestive Diseases (Shanghai), Gastrointestinal Early Cancer Prevention &amp; Treatment Alliance of China (GECA), Helicobacter pylori Study Group of Chinese Society of Gastroenterology, and Chinese Alliance for Helicobacter pylori Study. Chinese Consensus Report on Family-Based Helicobacter pylori Infection Control and Management (2021 Edition). Gut. 2022 Feb;71(2):238-253. doi: 10.1136/gutjnl-2021-325630. Epub 2021 Nov 26.</citation>
      <PMID>34836916</PMID>
    </results_reference>
    <results_reference>
      <citation>Liou JM, Malfertheiner P, Lee YC, Sheu BS, Sugano K, Cheng HC, Yeoh KG, Hsu PI, Goh KL, Mahachai V, Gotoda T, Chang WL, Chen MJ, Chiang TH, Chen CC, Wu CY, Leow AH, Wu JY, Wu DC, Hong TC, Lu H, Yamaoka Y, Megraud F, Chan FKL, Sung JJ, Lin JT, Graham DY, Wu MS, El-Omar EM; Asian Pacific Alliance on Helicobacter and Microbiota (APAHAM). Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020 Dec;69(12):2093-2112. doi: 10.1136/gutjnl-2020-322368. Epub 2020 Oct 1.</citation>
      <PMID>33004546</PMID>
    </results_reference>
    <results_reference>
      <citation>Moon SG, Lim CH, Kang HJ, Choi A, Kim S, Oh JH. Seven Days of Bismuth-Based Quadruple Therapy Is as Effective for the First-Line Treatment of Clarithromycin-Resistant Confirmed Helicobacter pylori Infection as 14 Days of Bismuth-Based Quadruple Therapy. J Clin Med. 2022 Jul 30;11(15):4440. doi: 10.3390/jcm11154440.</citation>
      <PMID>35956057</PMID>
    </results_reference>
    <results_reference>
      <citation>Qiao C, Li Y, Liu J, Ji C, Qu J, Hu J, Ji R, Wan M, Lin B, Lin M, Qi Q, Zuo X, Li Y. Clarithromycin versus furazolidone for naive Helicobacter pylori infected patients in a high clarithromycin resistance area. J Gastroenterol Hepatol. 2021 Sep;36(9):2383-2388. doi: 10.1111/jgh.15468. Epub 2021 Mar 10.</citation>
      <PMID>33691344</PMID>
    </results_reference>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 11, 2023</study_first_submitted>
    <study_first_submitted_qc>August 11, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 18, 2023</study_first_posted>
    <last_update_submitted>August 31, 2023</last_update_submitted>
    <last_update_submitted_qc>August 31, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 1, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>Shandong University</investigator_affiliation>
      <investigator_full_name>Yanqing Li</investigator_full_name>
      <investigator_title>Dr</investigator_title>
    </responsible_party>
    <intervention_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Amoxicillin</mesh_term>
      <mesh_term>Tetracycline</mesh_term>
      <mesh_term>Bismuth</mesh_term>
    </intervention_browse>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05997433
  org study id: SHARE2302
  nct id: NCT05997433
  lead sponsor: 
  collaborator: 
  collaborator: 
  collaborator: 
  collaborator: 
  collaborator: 
  collaborator: 
  is fda regulated drug: No
  is fda regulated device: No
  Helicobacter pylori (H. pylori) infection is a common global infectious disease of the
        gastrointestinal tract. Helicobacter pylori eradication can effectively prevent the
        development of stomach cancer.The researchers collect H.pylori-positive patients who need
        native therapy. The subjects were randomized to receive7 days and 14 days of bismuth
        quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the
        13C-urea breath test. Calculate the eradication rates, adverse reaction rates and patient
        compliance of each group.
  Related studies have shown that 7-day bismuth quadruple therapy is not inferior to 14-day
        bismuth quadruple therapy in the eradication of clarithromycin-resistant H. pylori.The
        results of the current study conducted by our team on the eradication of H. pylori in 10-day
        versus 14-day courses of bismuth quadruple therapy showed that the 10-days (92.09%) was not
        inferior to the 14-days(92.38%), but the incidence of adverse effects was significantly lower
        in the 10-day courses than in the 14-days(30.62%). If it can be demonstrated that the
        eradication rate of the 7-day course of bismuth quadruplex is close to that of the 14-days,
        then the 7-day course may be chosen.
  
        The researchers collect H.pylori-positive patients who need native therapy. If the subject
        meets the selection criteria but not the exclusion criteria, and signs an informed consent
        form, the researchers randomized the subjects in groups: subjects received 7days or 14days
        bismuth quadruple eradication therapy. The medication of groups are as follows. 6-8 weeks
        after the eradication treatment, the subjects will review the 13C-urea breath test, and the
        researcher records the results.
  
        After all subjects were tested, the eradication rates, adverse reaction rates and patient
        compliance of each group were calculated.
  
        According to therapy, it is randomized into a 7days treatment group and a 14 days treatment
        group. The two groups of bismuth quadruple regimens are the same, as follows:
  
        7days group: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid
        14days group: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid
  allocation: Randomized
  intervention model: Parallel Assignment
  intervention model description: Parallel Assignment
  primary purpose: Treatment
  masking: None (Open Label)
  measure: Eradication rate
  time frame: Immediately after follow-up check
  description: Both intention to treat (ITT) and per-protocol (PP) analyses will be used for the assessment of the eradication rates of Helicobacter pylori infections in two groups. The ITT analysis includes all randomly assigned patients who take at least one dose of the study medications. The PP analysis is limited to patients who take over 90% of the study medications and complete follow-up.
  measure: Rate of adverse reactions
  time frame: Immediately after follow-up check
  description: Rate of adverse reactions
  measure: Patient compliance
  time frame: Immediately after follow-up check
  description: Good compliance is defined as the actual dosage is within the range of 80%-100% of the dosage that should be taken.
  arm group label: 7 days
  arm group type: Experimental
  description: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid
  arm group label: 14 days
  arm group type: Active Comparator
  description: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid
  intervention type: Procedure
  intervention name: 7days bismuth quadruple
  description: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid*7days
  arm group label: 7 days
  other name: Amoxicillin
  other name: Tetracycline
  other name: Bismuth
  other name: Tegoprazan
  intervention type: Procedure
  intervention name: 14 days bismuth quadruple
  description: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid*14days
  arm group label: 14 days
  other name: Amoxicillin
  other name: Tetracycline
  other name: Bismuth
  other name: Tegoprazan
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: 70 Years
  healthy volunteers: No
  last name: Yanqing Li, Ph.D
  role: Principal Investigator
  affiliation: Qilu Hospital of Shandong University
  last name: Yanqing Li, Ph.D
  phone: +8653188369277
  email: liyanqing@sdu.edu.cn
  citation: Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong VWS, Wu JCY, Chan FKL, Sung JJY, Kaplan GG, Ng SC. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017 Aug;153(2):420-429. doi: 10.1053/j.gastro.2017.04.022. Epub 2017 Apr 27.
  PMID: 28456631
  citation: Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007 Jun;56(6):772-81. doi: 10.1136/gut.2006.101634. Epub 2006 Dec 14.
  PMID: 17170018
  citation: Cho JH, Jin SY. Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea. World J Clin Cases. 2022 Jul 6;10(19):6349-6359. doi: 10.12998/wjcc.v10.i19.6349.
  PMID: 35979311
  citation: Zhou XZ, Lyu NH, Zhu HY, Cai QC, Kong XY, Xie P, Zhou LY, Ding SZ, Li ZS, Du YQ; National Clinical Research Center for Digestive Diseases (Shanghai), Gastrointestinal Early Cancer Prevention & Treatment Alliance of China (GECA), Helicobacter pylori Study Group of Chinese Society of Gastroenterology and Chinese Alliance for Helicobacter pylori Study.. Large-scale, national, family-based epidemiological study on Helicobacter pylori infection in China: the time to change practice for related disease prevention. Gut. 2023 May;72(5):855-869. doi: 10.1136/gutjnl-2022-328965. Epub 2023 Jan 23.
  PMID: 36690433
  citation: Ding SZ, Du YQ, Lu H, Wang WH, Cheng H, Chen SY, Chen MH, Chen WC, Chen Y, Fang JY, Gao HJ, Guo MZ, Han Y, Hou XH, Hu FL, Jiang B, Jiang HX, Lan CH, Li JN, Li Y, Li YQ, Liu J, Li YM, Lyu B, Lu YY, Miao YL, Nie YZ, Qian JM, Sheng JQ, Tang CW, Wang F, Wang HH, Wang JB, Wang JT, Wang JP, Wang XH, Wu KC, Xia XZ, Xie WF, Xie Y, Xu JM, Yang CQ, Yang GB, Yuan Y, Zeng ZR, Zhang BY, Zhang GY, Zhang GX, Zhang JZ, Zhang ZY, Zheng PY, Zhu Y, Zuo XL, Zhou LY, Lyu NH, Yang YS, Li ZS; National Clinical Research Center for Digestive Diseases (Shanghai), Gastrointestinal Early Cancer Prevention & Treatment Alliance of China (GECA), Helicobacter pylori Study Group of Chinese Society of Gastroenterology, and Chinese Alliance for Helicobacter pylori Study. Chinese Consensus Report on Family-Based Helicobacter pylori Infection Control and Management (2021 Edition). Gut. 2022 Feb;71(2):238-253. doi: 10.1136/gutjnl-2021-325630. Epub 2021 Nov 26.
  PMID: 34836916
  citation: Liou JM, Malfertheiner P, Lee YC, Sheu BS, Sugano K, Cheng HC, Yeoh KG, Hsu PI, Goh KL, Mahachai V, Gotoda T, Chang WL, Chen MJ, Chiang TH, Chen CC, Wu CY, Leow AH, Wu JY, Wu DC, Hong TC, Lu H, Yamaoka Y, Megraud F, Chan FKL, Sung JJ, Lin JT, Graham DY, Wu MS, El-Omar EM; Asian Pacific Alliance on Helicobacter and Microbiota (APAHAM). Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020 Dec;69(12):2093-2112. doi: 10.1136/gutjnl-2020-322368. Epub 2020 Oct 1.
  PMID: 33004546
  citation: Moon SG, Lim CH, Kang HJ, Choi A, Kim S, Oh JH. Seven Days of Bismuth-Based Quadruple Therapy Is as Effective for the First-Line Treatment of Clarithromycin-Resistant Confirmed Helicobacter pylori Infection as 14 Days of Bismuth-Based Quadruple Therapy. J Clin Med. 2022 Jul 30;11(15):4440. doi: 10.3390/jcm11154440.
  PMID: 35956057
  citation: Qiao C, Li Y, Liu J, Ji C, Qu J, Hu J, Ji R, Wan M, Lin B, Lin M, Qi Q, Zuo X, Li Y. Clarithromycin versus furazolidone for naive Helicobacter pylori infected patients in a high clarithromycin resistance area. J Gastroenterol Hepatol. 2021 Sep;36(9):2383-2388. doi: 10.1111/jgh.15468. Epub 2021 Mar 10.
  PMID: 33691344
  responsible party type: Principal Investigator
  investigator affiliation: Shandong University
  investigator full name: Yanqing Li
  investigator title: Dr
  mesh term: Amoxicillin
  mesh term: Tetracycline
  mesh term: Bismuth